drugset
drugset / Trial / NCT02332798

Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia

NCT02332798 ↗

Phase 1 Completed 39 enrolled Biogen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study aims to assess the safety, tolerability and pharmacokinetics of PF-04958242 in multiple ascending doses in subjects with stable schizophrenia.

Timeline

Start
2015-01-06
Primary completion
2015-04-15
Completion
2015-04-15

Drugs

EvaluationDrugModalityDoseRoute
Subject PESAMPATOR Small molecule 0.25 mg —
Subject PESAMPATOR Small molecule 0.475 mg —

Indications

schizophrenia